NYU Langone Medical Center receives $5.4 million NYSTEM grant for stem cell research

June 21, 2010

NEW YORK, NY - June 21, 2010 - NYU Langone Medical Center has received a $5.4 million shared facility award from the Empire State Stem Cell Board's New York State Stem Cell Science (NYSTEM) program. The grant will be used to expand the NYU RNAi Core Facility and build shared access to the shRNA Core at Mount Sinai School of Medicine. The purpose of the collaboration is to provide stem cell researchers in New York State with a truly comprehensive, state-of-the-art facility to conduct high-throughput screening (HTS) to investigate gene function in cell based assays. The NYU RNAi Core Facility utilizes RNA interference (RNAi), an invaluable tool in the identification of new therapeutic targets, as well as novel methods for treatment of disease.

"We are truly honored to receive this award in recognition of the unique stem cell research being done at NYU Langone Medical Center," said Vivian S. Lee, MD, PhD, MBA, vice dean for science and chief scientific officer & senior vice president at NYU Langone Medical Center. "The NYU RNAi Core Facility demonstrates the Medical Center's commitment to cutting edge technologies to advance scientific discovery and change the landscape of health care."

The NYU RNAi Core Facility was established in June 2008 with generous support from the Helen L. and Martin S. Kimmel Center for Stem Cell Biology and the NYU Cancer Institute. Screens performed at the NYU RNAi screening facility aim to identify new therapeutic targets for the generation of cancer-stem cell-specific therapies. The facility also actively promotes an "open-access" policy in which it promotes the sharing of primary data to the scientific community by making the data generated from RNAi screens publicly available post-publication.

The NYU RNAi Core Facility is led by Ramanuj DasGupta, PhD, assistant professor in the Department of Pharmacology and research faculty at the NYU Cancer Institute and the Helen L. and Martin S. Kimmel Center for Stem Cell Biology at the Skirball Institute of Biomolecular Medicine. The facility is managed by Dr. Chi Yun, PhD, who serves as the assistant director of the NYU RNAi Core. Dr. DasGupta is working with co-principal investigator, Ihor Lemischka, PhD, professor of Gene and Cell Medicine and Developmental and Regenerative Biology at Mount Sinai School of Medicine.

"This multi-institutional grant will serve the entire academic community in the New York State and will provide a comprehensive set of cutting edge technologies to researchers working in stem cell-related research," said Ruth Lehmann, PhD, Director of the Center and of the Skirball Institute, the Laura and Isaac Perlmutter Chair, and a Howard Hughes investigator. "The funding provided by NYSTEM for the creation of this shared facility with molecular tools such as RNAi-based HTS will prove invaluable for the identification of new therapeutic targets."

The NYSTEM grant for shared facilities for stem cell research supports the establishment and operation of multi-institutional core research facilities to maximize the expertise, efficiency and quality of stem cell research in New York State. The grant is multi-institutional, serving the entire academic community in the New York State to promote a unique opportunity for fostering collaborations between different labs working with stem cells or conducting stem cell-related research. Covering up to four years, the grant will fund specialized resources and facilities to be operated on a shared-use basis in support of basic, applied, translational, pre-clinical or clinical stem cell-related research. Seven shared facility awards totaling more than $27 million were given out in the latest funding round.
-end-
More information on this award is available online at http://www.nyhealth.gov/press/releases/2010/2010-05-21_stem_cell_board_award.htm.

About NYU Langone Medical Center:


NYU Langone Medical Center is one of the nation's premier centers of excellence in healthcare, biomedical research, and medical education. For over 170 years, NYU physicians and researchers have made countless contributions to the practice and science of health care. Today the Medical Center consists of NYU School of Medicine, including the Smilow Research Center, the Skirball Institute of Biomolecular Medicine, and the Sackler Institute of Graduate Biomedical Sciences; and the NYU Hospitals Center, including Tisch Hospital, a 705-bed acute-care general hospital, Rusk Institute of Rehabilitation Medicine, the first and largest facility of its kind, and NYU Hospital for Joint Diseases, a leader in musculoskeletal care, a Clinical Cancer Center and numerous ambulatory sites.

NYU Langone Medical Center / New York University School of Medicine

Related Stem Cell Articles from Brightsurf:

Fat cell hormone boosts potential of stem cell therapy
Mesenchymal stem cell (MSC) therapy has shown promising results in the treatment of conditions ranging from liver cirrhosis to retinal damage, but results can be variable.

Oncotarget Characterization of iPS87, a prostate cancer stem cell-like cell line
Oncotarget Volume 11, Issue 12 reported outside its natural niche, the cultured prostate cancer stem cells lost their tumor-inducing capability and stem cell marker expression after approximately 8 transfers at a 1:3 split ratio.

Stem cell identity unmasked by single cell sequencing technology
Scientists from The University of Queensland's Diamantina Institute have revealed the difference between a stem cell and other blood vessel cells using gene-sequencing technology.

It's all about the (stem cell) neighborhood
Researchers at Duke-NUS Medical School have now identified how the stem cell neighbourhood, known as a niche, keeps stem cells in the gut alive.

Spaceflight activates cell changes with implications for stem cell-based heart repair
A new study of the effects of spaceflight on the development of heart cells identified changes in calcium signaling that could be used to develop stem cell-based therapies for cardiac repair.

Not just a stem cell marker
The protein CD34 is predominantly regarded as a marker of blood-forming stem cells but it helps with migration to the bone marrow too.

Interferon-beta producing stem cell-derived immune cell therapy on liver cancer
Induced pluripotent stem (iPS) cell-derived myeloid cells (iPS-ML) that produce the anti-tumor protein interferon-beta (IFN-beta) have been produced and analyzed by researchers from Kumamoto University, Japan.

Scientists aim to create the world's largest sickle cell disease stem cell library
Scientists at the Center for Regenerative Medicine at Boston Medical Center and Boston University School of Medicine are creating an induced pluripotent stem cell (iPSC)-based research library that opens the door to invaluable sickle cell disease research and novel therapy development.

Designer switches of cell fate could streamline stem cell biology
Researchers at the University of Wisconsin-Madison have developed a novel strategy to reprogram cells from one type to another in a more efficient and less biased manner than previous methods.

Allen Institute for cell science releases gene edited human stem cell lines
The Allen Institute for Cell Science has released the Allen Cell Collection: the first publicly available collection of gene edited, fluorescently tagged human induced pluripotent stem cells that target key cellular structures with unprecedented clarity.

Read More: Stem Cell News and Stem Cell Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.